Technical Papers

Mathematical Models

Carpenter D, Grimmer J. The Trouble with Deadlines. 2009.

Carpenter D, Ting M. A Theory of Approval Regulation. 2004.

endosub-20040214.pdf

Carpenter D, Ting M. “Regulatory Errors with Endogenous Agendas”. American Journal of Political Science . 2007;51 (4) :835-853.

regulatory_error_with_endogenous_agendas_-_ajpspublished.pdf

Carpenter D, Meier K, Krause G. Why Do Bureaucrats Delay? Lessons from a Stochastic Optimal Stopping Model of Product Approval” forthcoming. 2003.

Carpenter D. “Protection without Capture: Dynamic Product Approval by a Politically Responsive Learning Regulator”. American Political Science Review . 2004;98 (4) :613-631.

protwoc-apsr-pub.pdf

Empirical/Statistical Studies

Carpenter D, Feinstein B, Moore C, Turenne M, Yohai I, Zucker EJ. Why Do Bigger Firms Receive Faster Drug Approvals?. 2004.

whybigfast1.pdf

Carpenter D, Bowers J, Grimmer J, Moffitt S, Nall C, Zucker EJ. Deadline Effects in Regulatory Review: A Methodological and Empirical Analysis. 2007.

deadline-methods-pdufaclock-nomedjournalfigsortables-20070723.pdf

Carpenter D, Chattopadhyay J, Moffitt S, Nall C. The Complications of Controlling Agency Time Discretion: FDA Deadlines and Postmarket Drug Safety. American Journal of Political Science. 2012.

fdadeadlinesandsafety_ajps2012.pdf

Carpenter D, Moffitt S, Moore C, Rynbrandt R, Ting M, Yohai I, Zucker EJ. Early-Entrant Protection in Approval Regulation: Theory and Evidence from FDA Drug Review. Journal of Law Economics and Organization . 2010;26 (2).

Carpenter D. Groups the Media Agency Waiting Costs and FDA Drug Approval. American Journal of Political Science. 2002;46 (2) :490-505.

Carpenter D, Zucker EJ, Avorn J. Drug Review Deadlines and Subsequent Safety Problems. New England Journal of Medicine . 2008;358 (13) :1354-61.

See also: Regulations - Pharma

Copyright © 2024 The President and Fellows of Harvard College | Accessibility | Digital Accessibility | Report Copyright Infringement